A

argenx

Develops antibody-based therapies for autoimmune diseases

Market Head

Full-TimeUpdated on 10/4/2026
$236k - $324.5k/yr+ Short-term incentive program + Long-term incentive program
Expert
Bachelor's, Master's, MBA
Remote in USA
RemoteMust live within the market, which includes Alabama, Florida, Georgia, Puerto Rico, and the U.S. Virgin Islands. Travel up to 80% based on business needs; relocation benefits are not provided.

About the job

Requirements
  • A bachelor's degree is required; an advanced degree or MBA is preferred.
  • At least 15 years of progressive experience as a business leader with broad multi-therapeutic-area expertise, such as neurology, hematology, rheumatology, immunology, dermatology, or endocrinology.
  • A strong track record of driving business growth and achieving financial targets while balancing commercial performance with broader patient and market dynamics.
  • A track record of delivering sales success for rare disease products.
  • A customer-centric mindset and a successful track record of effective engagement and relationship building across diverse customer types and internal and external stakeholders, with a cross-therapeutic-area, portfolio-oriented mindset.
  • Experience with disease management and management of systematic treatments, including infusions and injections.
  • Successful experience working in strong cross-functional environments, including navigating and partnering with internal cross-functional leaders and non-commercial functions such as Market Access, Medical Affairs, and HUB/Patient Support teams.
  • Experience in biologics and with buy-and-bill customers, plus in-depth experience with the local healthcare ecosystem and dynamics, the U.S. healthcare and payer landscape, consumer types, business models, and evolving dynamics.
  • Ability to lead and collaborate effectively on cross-functional teams with varied technical expertise and backgrounds, with strong clinical, scientific, and business acumen.
  • Strong interpersonal, communication, and negotiation skills.
  • Strong analytical, problem-solving, and decision-making abilities, including prioritizing and managing complexity across multiple customer types and therapeutic areas.
  • Ability to translate market research and data-driven insights into actionable strategic initiatives.
  • Proficiency in Microsoft Office and Veeva.
  • Ability to work in an ambiguous environment undergoing transformation.
  • Passion for leadership and coaching, with comfort engaging in a culture of holistic feedback.
  • Flexibility to travel based on business needs, up to 80 percent.
  • Must live within the market; relocation benefits are not provided.
Responsibilities
  • Lead holistic local market business planning, including conducting market assessments, setting goals and priorities, and tailoring field deployment plans across roles, current and future indications, and therapeutic areas.
  • Define local key performance indicators, such as new patients on therapy versus total patients on therapy, in line with national metrics and guidelines.
  • Integrate multiple therapeutic areas into a single local market strategy, supporting Neuro and Rheumatology execution as well as future indications.
  • Identify new market opportunities, partnerships, growth levers, and revenue streams; identify innovative approaches to accelerate patient access and strengthen provider engagement.
  • Champion innovation to drive business growth and ensure adherence to legal, regulatory, and ethical standards, risk management, and compliance.
  • Build relationships with top and senior customers, including integrated delivery network leaders, regional payers, and providers, in coordination with Territory Business Managers, Field Reimbursement Managers, Territory Liaison Leads, Strategic Account Managers, Medical Science Liaisons, and Market Access account managers.
  • Ensure a coordinated, high-quality customer experience across touchpoints and cross-functional interactions within the local market.
  • Address local market barriers by mobilizing the appropriate functions to problem-solve together.
  • Champion a differentiated customer experience that positions argenx as a trusted partner across healthcare providers, patients, and market stakeholders.
  • Orchestrate cross-functional field roles across the market, using influence and enterprise leadership to align priorities, coordinate customer engagement, and ensure accountability for collective outcomes.
  • Provide market-level input and feedback on cross-functional contributions while functional coaching remains with discipline leaders.
  • Serve on Indication Strategy Teams, connecting local market insights with national strategy and serving as the local cross-functional lead for aligned indications.
  • Act as the connective hub between cross-functional leaders, balancing enterprise priorities with local market realities.
  • Ensure successful geographical execution of customer engagement.
  • Identify innovative solutions based on market dynamics.
  • Contribute to the Market Head community by sharing learnings and best practices and supporting capability building across markets.
  • Deliver holistic strategic execution across cross-functional teams and provide feedback to leaders about local market team performance.
  • Foster teamwork and a collaborative culture; champion and role-model argenx ways of working by empowering teams, creating channels for frontline voices, being entrepreneurial and customer-centric, executing with urgency, and acting as co-owners of the business.
  • Review and adapt business plans as needed in response to changing market conditions.
  • Analyze market trends, competitor activities, and industry dynamics to inform strategic decisions.
Desired Qualifications
  • An advanced degree or MBA.

About the company

argenx develops and markets antibody-based therapies for severe autoimmune diseases. Its medicines work by modulating the immune system through engineered antibodies, notably efgartigimod (VYVGART for generalized myasthenia gravis and VYVGART Hytrulo for CIDP) that influence FcRn pathways. The company differentiates itself through antibody engineering capabilities and a co-creation model with academic and industry partners, plus a pipeline focused on FcRn-, complement-, and target-directed programs across autoimmune indications. Its goal is to provide effective antibody medicines that improve patient outcomes and expand global access through its development and commercial footprint.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Amsterdam, Netherlands

Founded

2008

Get referred to argenx

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • May 8, 2026 FDA approval opened VYVGART to all adult gMG serotypes.
  • August 17, 2026 ALKIVIA met primary endpoint in autoimmune myositis, adding a multibillion-dollar indication.
  • September 29, 2026 AANEM data extended VYVGART into ocular MG and longer-duration CIDP use.

What critics are saying

  • UCB's RYSTIGGO and J&J's nipocalimab attack the same FcRn market by 2027.
  • VYVGART concentration remains extreme; one franchise drove $2.8 billion first-half 2026 sales.
  • If ALKIVIA or upcoming myositis filings disappoint, argenx loses its next blockbuster expansion.

What makes argenx unique

  • VYVGART is first-and-only approved for all adult gMG serotypes after May 8, 2026.
  • argenx scaled $1.5 billion Q2 2026 product sales with 60% year-over-year growth.
  • August 27, 2026 Forte acquisition added FB102, broadening the immunology pipeline.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

↑ 0%

1 year growth

↑ 0%

2 year growth

↑ 0%
Yahoo Finance
Oct 5th, 2026
10 analysts set Argenx price targets above $1,200 as biotech's revenue surges 60%

Argenx, a biopharmaceutical company with a market capitalisation near $60 billion, has caught the attention of Wall Street analysts. Ten analysts predict the biotech stock will reach at least $1,200 over the next 12 months, up from around $919 as of 2 October 2026. Wells Fargo and UBS set the highest price targets at $1,415 and $1,400 respectively, representing potential gains exceeding 50%. The average price target amongst 21 analysts stands at approximately $1,182, suggesting 29% upside. All but one analyst recommends buying the stock. Argenx's optimism stems from strong performance, delivering $1.5 billion in global product net sales last quarter, up 60% year over year. Its flagship drugs Vyvgart and Vyvgart Hytrulo drive growth, with additional approvals for autoimmune diseases potentially forthcoming.

ReachMD
Sep 30th, 2026
argenx to Present New VYVGART Data in MG and CIDP, Plus Pipeline Results, at AANEM 2026.

argenx to Present New VYVGART Data in MG and CIDP, Plus Pipeline Results, at AANEM 2026. 09/30/2026 Key Takeaways * argenx will present data on its portfolio and pipeline at the AANEM Annual Meeting and the MGFA Scientific Session, September 29 to October 2 in Orlando, Florida, including four oral presentations and dozens of posters. * New VYVGART (efgartigimod) results include deepening improvement in ocular myasthenia gravis (MG), sustained one-year efficacy in anti-AChR antibody-negative generalized MG (gMG), real-world data on earlier treatment, and long-term and switch data in chronic inflammatory demyelinating polyneuropathy (CIDP). * argenx will also present Phase 2 empasiprubart data in multifocal motor neuropathy (MMN) and Phase 1b adimanebart data in DOK7 congenital myasthenic syndrome (CMS). argenx, an Amsterdam-based immunology company, announced it will present clinical, long-term, and real-world data for VYVGART (intravenous efgartigimod alfa-fcab) and VYVGART Hytrulo (subcutaneous efgartigimod alfa and hyaluronidase-qvfc), along with results for two pipeline candidates. Chief Medical Officer Luc Truyen, M.D., Ph.D., said the data show how far the evidence for VYVGART reaches, across years of treatment and into patient populations historically left out of clinical trials. In MG, the company will present three sets of findings: * Ocular MG. In the Phase 3 ADAPT OCULUS study, patient-reported ocular scores on the Myasthenia Gravis Impairment Index (MGII) improved further after two VYVGART cycles beyond the placebo-controlled period. Scores went from -4.5 to -6.8 points in patients with anti-AChR antibodies and from -2.7 to -4.5 points in triple-seronegative patients. The company says the results build on evidence for VYVGART's potential as the first targeted treatment for ocular MG.

Yahoo Finance
Sep 26th, 2026
Argenx stock tipped for 23% gain on $1.5B revenue surge and Vyvgart expansion

Argenx stock has gained roughly 14% year-to-date, with Wall Street analysts projecting a potential 23% upside over the next 12 months. The biotech company has delivered 18 consecutive quarters of revenue growth. In Q2 2026, Argenx's global product net sales surged 60% year over year to $1.5 billion, with a 17% quarter-over-quarter increase. The Vyvgart franchise, treating chronic autoimmune disorders, drives growth following May 2026 FDA approval making it the first treatment for all serotypes of adults with generalised myasthenia gravis. Approximately 24,000 US patients receive treatment for chronic inflammatory demyelinating polyneuropathy, with half not well-managed on current therapy. Argenx reported positive Phase 3 results for Vyvgart in ocular myasthenia gravis earlier this year, with regulatory filing underway.

Radical Compliance
Sep 18th, 2026
Compliance Jobs Report: sept. 18.

Compliance Jobs Report: sept. 18. By Matt Kelly | September 18, 2026 This week the Compliance Jobs Report has a new top ethics and compliance dog at Uber, plus other hiring news at ATR, Argenx, Airbus, Bank of America, and several other places. Promotions to note at Kohler, RTX, Emerson, and more; job leads are in engineering, higher education, and banking. Plus its Meme of the Week! Radical Compliance gather the Jobs Report news items from LinkedIn, press releases, and wherever else Radical Compliance can find tips - and thank you to everyone who sends them in, you make the Jobs Report possible! If you have any gossip to share (even confidentially) email me at [email protected] or find me on LinkedIn. Compliance Jobs. This week Radical Compliance start with big news at Uber: the company has hired Matt Olsen as chief ethics, compliance, and security officer. Olsen comes to the ride-share giant from law firm Wilmer Hale, where he spent the last 18 months as chair of the firm's national security and government contracts practice; prior to that, he was assistant AG for national security at the Justice Department. Olson is the first permanent CCO at Uber since Scott Schools left the company in late 2024 to be head of compliance at OpenAI. (Technically, Heather Childs held the chief ethics and compliance role before Olsen; but she had been chief trust and security officer first and then Uber tacked the CCO title onto her portfolio before she left the company earlier this summer.) Michael Oren has joined Airbus as director of ethics and compliance. Oren previously worked at Lowe's Cos. as a director of compliance until earlier this spring. By the way, Radical Compliance is hearing still more rumors of departures within Centene Corp.'s compliance function, as first noted in last week's Jobs Report. Again, if you want to feed Radical Compliance more information, drop me a line at [email protected]! OneAscent, a financial services business in Birmingham, Ala., that caters to faith-based investment advisers, has named Monica Stoudemire chief compliance officer. Prior to OneAscent, Stoudemire was chief compliance officer at Bridgeworth Wealth Management, a Birmingham-based registered investment adviser with more than $2 billion in client assets. Ivana Popratnik has been hired at financial services firm Oanda as chief compliance officer. Popratnik comes to Oanda after four years at TastyFx, where she most recently had been compliance officer. Memorial Healthcare System in Hollywood, Fla., has hired Daniel Villavisanis as director of corporate compliance. Villavisanis comes to Memorial after not quite three years at United Surgical Partners International, where he had been a compliance officer. Bolton Clarke, an assisted-living healthcare system in Australia, has tapped Stephanie Brown as head of internal audit. Brown previously worked as director of audit, risk, and compliance at the Department of Natural Resources in Queensland. Michael Grace has delivered himself to shipping and logistics firm Freight Flex, where he is chief compliance officer. Grace comes to Freight Flex from Highway, a business that helps track the identities of freight carriers, where he had been vice president of customer risk management. Brian Stachow has joined Argenx as as associate director of ethics and compliance training. Stachow comes to the mid-sized biotech firm from Agilent Technologies, where he had been an instructional designer. Altruist, a "tech-forward wealth platform" for independent financial advisers, has hired Nina Karbaum as director of compliance. Karbaum formerly worked at FINRA (the regulator for broker-dealers) where she had been a regulatory examiner until August. French aircraft manufacturer ATR has hired Stefano Spanò as chief compliance officer. Spanò joins ATR, a maker of turbo-prop jets for regional travel, after 11 years at Italian defense contractor Leonardo, where he had most recently been a senior trade compliance officer. Emirates NBD, one of the larger banks in the Middle East, has tapped Mohammed Samir as chief audit executive for the bank's Egypt operations. Samir comes to Emirates from Abu Dhabi Commercial Bank, where he had also been chief audit executive since. 2020. Dhiman Biswas has a new job as senior manager of compliance analytics at Bank of America. Biswas previously worked at Collabera as a project management consultant and prior to that was a business analytics specialist at MassMutual. Curia, a contract manufacturing business in the pharmaceutical sector, has hired Vicki Jackson as quality compliance manager. Jackson was last seen at Otsuka ICU Medical, where she had been an audit manager. And Seth Herrington has joined Map Transit, a freight forwarding business in Florida, as compliance coordinator. Herrington had previously been in the U.S. Marine Corps working on regulatory compliance issues for the Office of the Inspector General and just wrapped up a college degree at the University of Central Florida. Welcome to the profession, Mr. Herrington. Moving up the ladder. Akuvo, a maker of AI-powered software for collections and credit risk management, has promoted Molly DeMarcus from senior launch adviser to model governance compliance analyst (a title I suspect Radical Compliance'll see more often in its AI-enhanced future). Bath and kitchen products manufacturer Kohler has promoted Dan Rieland from manager of codes and standards to senior manager for product regulatory compliance. Katelyn Weese has moved up the ladder at defense contractor RTX Corp. Weese had worked for several years in various roles supporting the RTX board; now she's associate director of the global ethics and compliance program. Electric equipment manufacturer Emerson has promoted Michael Gilchrist from senior associate general counsel to vice president for regulatory compliance. Rody Lingiah has a new role within the Capgemini empire. He had been an export control officer for the firm's Sogeti subsidiary; now he's export control manager for Capgemini Engineering. Siemens Healthineers has promoted Ievgeniia Vasylchenko to chief compliance officer for central and eastern Europe. Vasylchenko had previously ran compliance for Siemens' lab diagnostics business in the region and was regional compliance officer for Ukraine. Open req orders. Engineering and professional services giant KBR is seeking a staff attorney for its anti-corruption and business integrity team. Job can be based in either Houston or Arlington, Va.; salary range not provided. Looks like KBR is hiring for a few other ethics and compliance roles, too. Tufts University is looking for a privacy program manager. Job is based in Medford, Mass., just outside Boston. Salary range is $108,000 to $162,000. MVB Bank is hiring a director of fair banking compliance and enterprise compliance advisory. The job can be remote, although MVB's headquarters are in West Virginia. No salary range provided. #NotCool Compliance Meme of the Week. That's all for this week's report. As always, if you have a tip or want to brag about your new job, promotion, career milestone, or anything else, email me at [email protected] or find me on LinkedIn. I'm always happy to give credit to the many hard-working people here in its corner of the business universe. Posted in News

Associated Press
Sep 17th, 2026
argenx appoints Thomas M. Brakel and Khurem Farooq as non-executive directors

argenx SE, a global immunology innovation company, has appointed Thomas M. Brakel and Khurem Farooq as non-executive directors to its Board of Directors. The appointments were announced following the company's Extraordinary General Meeting of Shareholders. Tim Van Hauwermeiren, chairperson of the board, said the new directors bring valuable leadership and expertise as argenx works towards its Vision 2030 goals. The company develops antibody-based medicines for autoimmune diseases and has commercialised the first approved neonatal Fc receptor blocker. Voting results and related documents from the shareholders' meeting are available on the argenx website. The company partners with academic researchers to translate immunology research into treatments for diseases with high unmet medical needs.